Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Qinghai Spring Medicinal Resources Technology Co PS Ratio Related Terms
Qinghai Spring Medicinal Resources Technology Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co PS Ratio Chart
Qinghai Spring Medicinal Resources Technology Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qinghai Spring Medicinal Resources Technology Co PS Ratio vs Drug Manufacturers Industry
Qinghai Spring Medicinal Resources Technology Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Qinghai Spring Medicinal Resources Technology Co's Share Price of today is ¥3.77. Qinghai Spring Medicinal Resources Technology Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a PS Ratio of 6.38 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. This is 48% below median its historical median of 12.36. Over the past decade, Qinghai Spring Medicinal Resources Technology Co's PS Ratio has ranged from 3.97 to 73.67. According to the industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #755 out of 952 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Qinghai Spring Medicinal Resources Technology Co's PS Ratio too high?
Qinghai Spring Medicinal Resources Technology Co's current PS Ratio of 6.38 is 48% below median its 10-year median of 12.36. Over the past 10 years, this metric has ranged from a low of 3.97 to a high of 73.67. The Drug Manufacturers industry median PS Ratio is 2.24. Qinghai Spring Medicinal Resources Technology Co's value of 6.38 is 184.8% above this industry median. Based on the distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #755 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #755 out of 952 companies for PS Ratio. This places Qinghai Spring Medicinal Resources Technology Co in the lower half of its industry. The industry median PS Ratio is 2.24. Qinghai Spring Medicinal Resources Technology Co's value of 6.38 is 184.8% above this benchmark. Historically, Qinghai Spring Medicinal Resources Technology Co's own PS Ratio has ranged from 3.97 to 73.67 over the past decade. While the company's 10-year median is 12.36 vs. the industry median of 2.24, Qinghai Spring Medicinal Resources Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.24, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qinghai Spring Medicinal Resources Technology Co's current PS Ratio of 6.38 is 184.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qinghai Spring Medicinal Resources Technology Co's current PS Ratio is 6.38, which is 48% below median its own 10-year median of 12.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥5.86, compared to a current price of ¥3.77 — trading 35.7% below its estimated fair value. The current PS Ratio is 6.38, which is 48% below median its 10-year median of 12.36 and 184.8% above the Drug Manufacturers industry median of 2.24. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current PS Ratio is 6.38 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued.
The current stock price of ¥3.77 is trading 35.7% below its estimated GF Value™ of ¥5.86.
GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Significantly Undervalued.
Key valuation signals for SHSE:600381:
PS Ratio: 6.38 (48% below median its 10-year median of 12.36)
GF Value™: ¥5.86 vs. price of ¥3.77 (35.7% below fair value)
Industry Position: 184.8% above the Drug Manufacturers median (#755 of 952)
No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qinghai Spring Medicinal Resources Technology Co Business Description
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
62GF Score
Get the complete analysis for SHSE:600381
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600381 has been successfully added to your 
